دورية أكاديمية
Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.
العنوان: | Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators. |
---|---|
المؤلفون: | Amin OE; Division of Infection & Immunity, Institute of Immunity & Transplantation, University College London, London, United Kingdom., Colbeck EJ; Division of Infection & Immunity, Institute of Immunity & Transplantation, University College London, London, United Kingdom., Daffis S; Gilead Sciences Inc., Foster City, CA., Khan S; Gilead Sciences Inc., Foster City, CA., Ramakrishnan D; Gilead Sciences Inc., Foster City, CA., Pattabiraman D; Gilead Sciences Inc., Foster City, CA., Chu R; Gilead Sciences Inc., Foster City, CA., Micolochick Steuer H; Gilead Sciences Inc., Foster City, CA., Lehar S; Gilead Sciences Inc., Foster City, CA., Peiser L; Gilead Sciences Inc., Foster City, CA., Palazzo A; Gilead Sciences Inc., Foster City, CA., Frey C; Gilead Sciences Inc., Foster City, CA., Davies J; Division of Infection & Immunity, Institute of Immunity & Transplantation, University College London, London, United Kingdom., Javanbakht H; Gilead Sciences Inc., Foster City, CA., Rosenberg WMC; Institute for Liver and Digestive Health, University College London, London, United Kingdom., Fletcher SP; Gilead Sciences Inc., Foster City, CA., Maini MK; Division of Infection & Immunity, Institute of Immunity & Transplantation, University College London, London, United Kingdom., Pallett LJ; Division of Infection & Immunity, Institute of Immunity & Transplantation, University College London, London, United Kingdom. |
المصدر: | Hepatology (Baltimore, Md.) [Hepatology] 2021 Jul; Vol. 74 (1), pp. 55-71. Date of Electronic Publication: 2021 Jun 20. |
نوع المنشور: | Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 8302946 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-3350 (Electronic) Linking ISSN: 02709139 NLM ISO Abbreviation: Hepatology Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2023- : [Philadelphia] : Wolters Kluwer Health, Inc. Original Publication: Baltimore, MD : Williams & Wilkins, [c1981]- |
مواضيع طبية MeSH: | Antiviral Agents/*pharmacology , Hepatitis B, Chronic/*drug therapy , Hexanols/*pharmacology , Pyrimidines/*pharmacology , Toll-Like Receptor 8/*antagonists & inhibitors, Adult ; Aged ; Animals ; Antiviral Agents/therapeutic use ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/immunology ; Cohort Studies ; Disease Models, Animal ; Female ; Healthy Volunteers ; Hep G2 Cells ; Hepatitis B, Chronic/immunology ; Hepatitis B, Chronic/virology ; Hexanols/therapeutic use ; Host-Pathogen Interactions/drug effects ; Host-Pathogen Interactions/immunology ; Humans ; Killer Cells, Natural/drug effects ; Killer Cells, Natural/immunology ; Leukocytes, Mononuclear ; Male ; Marmota ; Middle Aged ; Primary Cell Culture ; Pyrimidines/therapeutic use ; T-Lymphocytes, Regulatory/drug effects ; T-Lymphocytes, Regulatory/immunology ; Toll-Like Receptor 8/metabolism ; Young Adult |
مستخلص: | Background and Aims: GS-9688 (selgantolimod) is a toll-like receptor 8 agonist in clinical development for the treatment of chronic hepatitis B (CHB). Antiviral activity of GS-9688 has previously been evaluated in vitro in HBV-infected hepatocytes and in vivo in the woodchuck model of CHB. Here we evaluated the potential of GS-9688 to boost responses contributing to viral control and to modulate regulatory mediators. Approach and Results: We characterized the effect of GS-9688 on immune cell subsets in vitro in peripheral blood mononuclear cells of healthy controls and patients with CHB. GS-9688 activated dendritic cells and mononuclear phagocytes to produce IL-12 and other immunomodulatory mediators, inducing a comparable cytokine profile in healthy controls and patients with CHB. GS-9688 increased the frequency of activated natural killer (NK) cells, mucosal-associated invariant T cells, CD4 + follicular helper T cells, and, in about 50% of patients, HBV-specific CD8 + T cells expressing interferon-γ. Moreover, in vitro stimulation with GS-9688 induced NK-cell expression of interferon-γ and TNF-α, and promoted hepatocyte lysis. We also assessed whether GS-9688 inhibited immunosuppressive cell subsets that might enhance antiviral efficacy. Stimulation with GS-9688 reduced the frequency of CD4 + regulatory T cells and monocytic myeloid-derived suppressor cells (MDSCs). Residual MDSCs expressed higher levels of negative immune regulators, galectin-9 and programmed death-ligand 1. Conversely, GS-9688 induced an expansion of immunoregulatory TNF-related apoptosis-inducing ligand + NK cells and degranulation of arginase-I + polymorphonuclear MDSCs. Conclusions: GS-9688 induces cytokines in human peripheral blood mononuclear cells that are able to activate antiviral effector function by multiple immune mediators (HBV-specific CD8 + T cells, CD4 + follicular helper T cells, NK cells, and mucosal-associated invariant T cells). Although reducing the frequency of some immunoregulatory subsets, it enhances the immunosuppressive potential of others, highlighting potential biomarkers and immunotherapeutic targets to optimize the antiviral efficacy of GS-9688. (© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.) |
References: | J Clin Invest. 2018 Oct 1;128(10):4573-4587. (PMID: 30084841) J Exp Med. 2007 Mar 19;204(3):667-80. (PMID: 17353365) Lancet Infect Dis. 2007 Dec;7(12):804-13. (PMID: 18045563) J Hepatol. 2018 Mar;68(3):431-440. (PMID: 29104121) Sci Rep. 2016 May 23;6:26157. (PMID: 27210614) J Clin Invest. 2018 Oct 1;128(10):4588-4603. (PMID: 30091725) Hepatology. 2005 Nov;42(5):1028-36. (PMID: 16250037) Gastroenterology. 2018 Jun;154(8):2222-2236. (PMID: 29544722) J Virol. 2009 Dec;83(23):12266-78. (PMID: 19740992) Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184. (PMID: 30647010) Immunity. 2011 Jan 28;34(1):108-21. (PMID: 21215658) J Hepatol. 2015 Jun;62(6):1237-45. (PMID: 25559326) PLoS Pathog. 2013 Mar;9(3):e1003208. (PMID: 23516358) Hepatology. 2011 May;53(5):1494-503. (PMID: 21360567) Gut. 2019 Aug;68(8):1493-1503. (PMID: 30487267) Curr Opin Virol. 2016 Jun;18:135-43. (PMID: 27447092) Sci Transl Med. 2018 Mar 21;10(433):. (PMID: 29563320) Cell Rep. 2016 Aug 2;16(5):1243-1252. (PMID: 27452473) J Virol. 1997 Apr;71(4):3236-43. (PMID: 9060687) Front Immunol. 2013 Mar 01;4:57. (PMID: 23459859) J Exp Med. 2010 Jun 7;207(6):1261-71. (PMID: 20479117) J Immunol. 2005 Feb 1;174(3):1259-68. (PMID: 15661881) Clin Cancer Res. 2018 Jan 1;24(1):62-72. (PMID: 29061643) Immunity. 2011 Jun 24;34(6):932-46. (PMID: 21636296) PLoS Pathog. 2014 Jun 26;10(6):e1004210. (PMID: 24967632) J Med Chem. 2020 Sep 24;63(18):10188-10203. (PMID: 32407112) J Virol. 2007 Apr;81(8):4215-25. (PMID: 17287266) J Hepatol. 2016 Apr;64(1 Suppl):S71-S83. (PMID: 27084039) Hepatology. 2009 Nov;50(5):1625-37. (PMID: 19739236) Nat Immunol. 2018 Apr;19(4):386-396. (PMID: 29556002) PLoS One. 2012;7(10):e47648. (PMID: 23112829) Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3764-8. (PMID: 8170985) J Leukoc Biol. 2018 Jan;103(1):157-164. (PMID: 29345064) J Virol. 2003 Jan;77(1):68-76. (PMID: 12477811) J Hepatol. 2000 Feb;32(2):317-24. (PMID: 10707873) Gastroenterology. 2009 Sep;137(3):1151-60, 1160.e1-7. (PMID: 19470388) J Exp Med. 2000 Apr 17;191(8):1269-80. (PMID: 10770795) Nat Med. 2015 Jun;21(6):591-600. (PMID: 25962123) J Exp Med. 2013 Jan 14;210(1):99-114. (PMID: 23254287) J Hepatol. 2018 May;68(5):912-921. (PMID: 29247724) Trends Immunol. 2016 Mar;37(3):208-220. (PMID: 26858199) Int Immunol. 2006 Jul;18(7):1115-26. (PMID: 16728430) Sci Rep. 2017 Jul 17;7(1):5514. (PMID: 28717244) J Exp Med. 2017 Jun 5;214(6):1567-1580. (PMID: 28526759) J Hepatol. 2018 May;68(5):922-931. (PMID: 29247725) Nat Rev Immunol. 2014 Oct;14(10):667-85. (PMID: 25234148) J Viral Hepat. 2018 Nov;25(11):1331-1340. (PMID: 29851204) Immunity. 2009 Jul 17;31(1):158-69. (PMID: 19592276) Gastroenterology. 2013 Jun;144(7):1508-17, 1517.e1-10. (PMID: 23415804) Lancet Gastroenterol Hepatol. 2018 Mar;3(3):192-202. (PMID: 29870733) Science. 2005 Aug 26;309(5739):1380-4. (PMID: 16123302) Nat Med. 2017 Mar;23(3):327-336. (PMID: 28165481) Hepatology. 2021 Jan;73(1):53-67. (PMID: 32246499) |
معلومات مُعتمدة: | 26603 United Kingdom CRUK_ Cancer Research UK |
المشرفين على المادة: | 0 (Antiviral Agents) 0 (Hexanols) 0 (Pyrimidines) 0 (TLR8 protein, human) 0 (Toll-Like Receptor 8) RM4GJT3SMQ (selgantolimod) |
تواريخ الأحداث: | Date Created: 20201228 Date Completed: 20220104 Latest Revision: 20240210 |
رمز التحديث: | 20240210 |
مُعرف محوري في PubMed: | PMC8436741 |
DOI: | 10.1002/hep.31695 |
PMID: | 33368377 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!